1312547-19-5

1312547-19-5 structure

Name: Samatasvir
Chemical Name: samatasvir
CAS Number: 1312547-19-5
Molecular Formula: C₄₇H₄₈N₈O₆S₂
Molecular Weight: 885.064
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2020-01-11 19:20:50
Modify Date: 2024-06-07 23:52:24
Samatasvir (IDX719) is a highly potent, selective inhibitor of HCV NS5A that effectively inhibits HCV genotype 1-5 replicons with EC50 of 2-24 pM; also retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals; demonstrates an overall additive effect when combined with IFN-α, ribavirin, representative HCV protease, and nonnucleoside polymerase inhibitors or the nucleotide prodrug IDX184. HCV Infection Phase 2 Clinical

Name	samatasvir
Synonyms	Carbamic acid, N-[(1R)-2-[(2S)-2-[4-[4-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-5-yl]thieno[3,2-b]thien-3-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester Methyl {(1R)-2-[(2S)-2-{4-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}-1-pyrrolidinyl]-2-oxo-1-phenylethyl}carbamate samatasvir IDX18719

Description	Samatasvir (IDX719) is a highly potent, selective inhibitor of HCV NS5A that effectively inhibits HCV genotype 1-5 replicons with EC50 of 2-24 pM; also retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals; demonstrates an overall additive effect when combined with IFN-α, ribavirin, representative HCV protease, and nonnucleoside polymerase inhibitors or the nucleotide prodrug IDX184. HCV Infection Phase 2 Clinical
References	References 1. Bilello JP, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4431-42. 2. Vince B, et al. J Hepatol. 2014 May;60(5):920-7. View Related Products by Target HCV HCV Infection